Mr. J is being monitored on the cardiac floor on telemetry. His rhythm has been normal sinus rhythm. The monitor alarm alerts the nurse that Mr. J's rhythm is now a straight line on the monitor. The nurse's first action is to:

A. Mask an early sign of hypoglycemia: Atenolol is a beta-adrenergic blocker that can blunt sympathetic nervous system responses, such as tachycardia and tremors, which are early warning signs of hypoglycemia. Diabetic patients taking atenolol may not recognize low blood sugar until more severe symptoms, like dizziness or confusion, occur, so monitoring glucose closely is essential.

B. Cause hyperglycemia: Atenolol does not directly raise blood glucose levels. While nonselective beta-blockers may slightly affect glucose metabolism, atenolol, a cardioselective beta-1 blocker, is unlikely to cause clinically significant hyperglycemia in most patients.

C. Increase the action of insulin: Atenolol does not enhance insulin’s effect. Its primary actions are on heart rate and cardiac output, not insulin sensitivity or glucose uptake, so this reflects a misunderstanding of the drug’s pharmacology.

D. Decrease the action of insulin: Atenolol does not directly inhibit insulin activity. Although beta-blockers may interfere with certain metabolic responses, atenolol does not significantly alter insulin effectiveness, making this an incorrect understanding.

A. Bundle branch block: A bundle branch block is a conduction delay in the ventricular pathways, which affects the QRS complex but does not itself cause tachyarrhythmias. Amiodarone is not indicated for isolated bundle branch block and would not correct this conduction abnormality.

B. Ventricular tachycardia: Amiodarone is a class III antiarrhythmic used to treat life-threatening ventricular arrhythmias, including sustained ventricular tachycardia and ventricular fibrillation. It works by prolonging the action potential and refractory period, stabilizing the myocardium and reducing the likelihood of recurrent episodes.

C. Junctional rhythm: Junctional rhythms originate from the AV node, typically with a slow rate. These rhythms are generally not treated with amiodarone unless they are associated with other dangerous arrhythmias. Junctional rhythms are usually managed based on rate and hemodynamic stability.

D. Sinus bradycardia: Sinus bradycardia is characterized by a slow but regular heart rhythm originating from the SA node. Amiodarone can actually worsen bradycardia and is not indicated for this rhythm. Management typically involves observation or medications such as atropine if symptomatic.